<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02672683</url>
  </required_header>
  <id_info>
    <org_study_id>AOR 14086</org_study_id>
    <nct_id>NCT02672683</nct_id>
  </id_info>
  <brief_title>Non Invasive Detection of Cardiac Allograft Rejection by Circulating microRNAs</brief_title>
  <acronym>MIRRACLE</acronym>
  <official_title>Non Invasive Detection of Acute Rejection by Circulating microRNAs in Cardiac Transplantation: a Multicenter Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the level of expression of 4 circulating microRNAs&#xD;
      in the serum using RT-PCR. A pilote study with cardiac transplant patients has shown that&#xD;
      expression of these microRNAs could discriminate patients with a histologically proven&#xD;
      rejection from patient displaying a normal endomyocardial biopsy. The signature must be&#xD;
      confirmed in unselected patients and its stability evaluated according to clinical,&#xD;
      biological and immunological parameters of included patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart transplantation is the only available long-term treatment option for patients with&#xD;
      terminal heart failure.&#xD;
&#xD;
      Despite considerable progress in immunosuppressive regimens, allograft rejection remains a&#xD;
      major cause of graft loss.&#xD;
&#xD;
      Majority of cardiac allograft rejection are asymptomatic. Only severe rejection goes along&#xD;
      with cardiac dysfunction. This clinical latency makes the cardiac rejection diagnostic&#xD;
      difficult and has ruled modalities of detection of cardiac rejection.&#xD;
&#xD;
      The cornerstone of rejection diagnosis and post-transplant follow-up relies on endomyocardial&#xD;
      biopsy (EMB) and classical histopathology assessment. Echocardiography and MRI are neither&#xD;
      sensitive nor specific enough to replace EMB. Majority of transplant centers thus evaluate&#xD;
      rejection using iterative protocol biopsies. These cardiac allograft monitoring protocols are&#xD;
      heavy, with 15 to 20 EMB in the first year of transplantation and 1 to 2 EMB each year after&#xD;
      the first year. EMB are invasive procedure with a low but not zero risk of severe adverse&#xD;
      events. Repetition of EMB is associated with tricuspid regurgitation due to valvular&#xD;
      complications. Moreover incidence of cardiac rejection explains the cost-effectiveness of&#xD;
      EMBs: 50 to 70% of biopsies are normal.&#xD;
&#xD;
      The goal is thus to detect rejection in the blood by measuring expression levels of 4&#xD;
      circulating microRNAs in patients' sera by RT-PCR. The seric expression levels of these 4&#xD;
      circulating microRNAs will be compared to the histopathological diagnosis made on concomitant&#xD;
      endomyocardial biopsy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2016</start_date>
  <completion_date type="Actual">March 26, 2019</completion_date>
  <primary_completion_date type="Actual">April 20, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of circulating MicroRNAs measurement in serum with histopathological diagnosis of rejection on concomitant endomyocardial biopsy</measure>
    <time_frame>one month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of circulating MicroRNAs measurement in serum with histopathological diagnosis of rejection on concomitant endomyocardial biopsy</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of circulating MicroRNAs measurement in serum with histopathological diagnosis of rejection on concomitant endomyocardial biopsy</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of circulating MicroRNAs measurement in serum with histopathological diagnosis of rejection on concomitant endomyocardial biopsy</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of circulating MicroRNAs measurement in serum with histopathological diagnosis of rejection on concomitant endomyocardial biopsy</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">461</enrollment>
  <condition>Cardiac Transplantation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a cardiac transplant&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a cardiac transplant at the time of inclusion&#xD;
&#xD;
          -  Patients transplanted for less than 10 years and having an annual follow-up&#xD;
&#xD;
          -  Patients with a biopsy evaluation during their follow-up, at month 1, 3, 6, 12 (newly&#xD;
             transplanted) and annually (newly and already transplanted patients) and concomitant&#xD;
             routine blood work&#xD;
&#xD;
          -  Patients not opposed to the study&#xD;
&#xD;
          -  Patients with assessment of anti-donor specific antibodies during the study period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a multi-organ transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-paul Duong Van Huyen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Necker Hospital, AP-HP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PARCC/ INSERM U970, Team 4, Xavier Jouven, Cardiovascular epidemiology and sudden death, Georges Pompidou European Hospital,</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://dx.doi.org/10.1093/eurheartj/ehu346</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Duong Van Huyen JP, Tible M, Gay A, Guillemain R, Aubert O, Varnous S, Iserin F, Rouvier P, François A, Vernerey D, Loyer X, Leprince P, Empana JP, Bruneval P, Loupy A, Jouven X. MicroRNAs as non-invasive biomarkers of heart transplant rejection. Eur Heart J. 2014 Dec 1;35(45):3194-202. doi: 10.1093/eurheartj/ehu346. Epub 2014 Aug 31.</citation>
    <PMID>25176944</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 30, 2015</study_first_submitted>
  <study_first_submitted_qc>January 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2016</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

